Alterity Therapeutics Ltd has released a press release.
Alterity Presents New Data on Multiple System Atrophy
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Alterity Granted New Composition of Matter Patent in Europe
- Alterity receives a $4.74 million R&D Tax Refund
- Ph 2 Data Monitoring Committee Recommends Continuing Trial
- Investor Presentation
- ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
Later from Alterity Therapeutics
- Appendix 4E and Annual Report 2023
- ATH completes enrolment in ATH434-201 Phase 2 clinical trial
- Alterity Therapeutics Raises $4.8M AUD in Placement
- Positive Efficacy Data for ATH434 in a Primate Model of PD
- Phase 2 DMC Recommends Continuing Clinical Trial as Planned
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics